Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events in the semaglutide group compared to placebo. Evidence Ra ...

TrialGPT, developed by the National Institutes of Health, matches patients to clinical trials with 87.3 percent accuracy2.